Literature and evidence database
Find the source, the model and the boundary.
Search source records connected to the product-family knowledge base. Filter by category, product, publication year, research type, study model and editorial evidence tier.
Product evidence maps
A focused source set for each product.
Search and filter
Evidence records
Narrow the records by product, year or study model. Open each source to check its results and limitations.
JPT: peptide pools and matrix layouts
JPT: peptide pools and matrix layouts. Accessed 2026-10-03.
Gonadotropin strategies in congenital hypogonadotropic hypogonadism
2026 open-label randomized study of 45 men; PMID 41993983.
FOXO4-DRI and endothelial-cell senescence
2026 endothelial and mouse-aging-model study; PMID 41625068.
TGA finds inconsistent Melanotan II content
Official August 2026 laboratory-testing safety alert.
REIMAGINE 2 cagrilintide-semaglutide comparative phase 3 study
2026 comparative trial; PMID 42251859.
ZEPBOUND (tirzepatide) prescribing information
U.S. FDA. Revised 2026. NDA 217806.
What to know about retatrutide
Eli Lilly and Company. Medically reviewed; updated July 2026.
Epitalon and telomere length in human cell lines
Cell study. 2025. PMID 40908429.
Randomized trial involving human menopausal gonadotropin
Clinical trial. 2025. PMID 40193016.
KPV mitigates fine-dust-induced keratinocyte apoptosis and inflammation
Cell study. 2025. PMID 40073467.
PNC-27 experimental antitumor study
Preclinical study. 2025. PMID 40750238.
Semax targets Oprm1 in a spinal-cord-injury mouse model
Preclinical study. 2025. PMID 40692165.
FDA Drug Trials Snapshot: Forzinity
U.S. FDA. Approval date September 19, 2025; SPIBA-201 population and endpoint record.
EGRIFTA WR (tesamorelin) prescribing information
U.S. Food and Drug Administration. 2025 labeling record for BLA 022505.
MOUNJARO (tirzepatide) current prescribing information
U.S. Food and Drug Administration. Revised December 2025. Initial U.S. approval 2022.
Emerging Use of BPC-157 in Orthopaedic Sports Medicine
Systematic review. 2025. PMID 40756949.
Multifunctionality and Possible Medical Application of the BPC 157 Peptide
Literature and patent review. 2025. PMID 40005999.
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
N Engl J Med. 2025. PMID 40544433.
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
N Engl J Med. 2025. PMID 40544432.
DailyMed Oxytocin Injection, USP label
Official U.S. prescription label, updated March 2025.
TESTS phase 3 thymosin alpha-1 sepsis trial
Primary 2025 multicenter trial; PMID 39814420.
GHRP-6 in doxorubicin-induced injury
Preclinical study. 2024. PMID 38873418.
Glutathione for skin health: systematic review
Systematic review. 2024. PMID 39444151.
SCENESSE (afamelanotide) prescribing information
U.S. FDA label, revised 2024.
Oxytocin physiology and pharmacology
Review. 2024. PMID 38462255.
PNC-27 membrane-associated anticancer research
Preclinical study. 2024. PMID 38802154.
ACTH-like peptides and rat brain gene expression after ischemia
Preclinical study. 2024. PMID 39767736.
Clinical evaluation of a dual anti-wrinkle dissolving microneedle patch
Shin JY, et al. Ann Dermatol. 2024. PMID 39082657.
Thymalin in rat mandibular regeneration
Preclinical study. 2024. PMID 38642352.
Editorial methodology
How records are classified
Records are deduplicated by source URL and linked to every relevant product family. Study type and model are inferred from the citation and editorial evidence label, then reviewed during content QA.
Read the full editorial, AI-assistance and correction policy →
Labels and databases supporting regulatory status, formulation or chemical identity.
Controlled trials, systematic reviews and other clinical records with population-specific interpretation.
Animal, cell, analytical and mechanistic records that cannot establish human outcomes.
Narrative reviews, registries and sponsor reports kept visibly distinct from peer-reviewed outcomes.
Use the records
